Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder
October 10, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree
September 24, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
September 19, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
August 28, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
August 19, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus Announces Second Quarter 2024 Financial Results
August 06, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
August 01, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024
July 23, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
May 30, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy
May 23, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
May 09, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus Announces First Quarter 2024 Financial Results
May 08, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story
May 01, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
April 24, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus Provides Regulatory Update for SPN-830
April 08, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus to Participate in Two Upcoming Investor Conferences
March 06, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference
February 28, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus Announces Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024
February 13, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent
February 05, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus Announces Third Quarter 2023 Financial Results
November 08, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus to Participate in the Jefferies London Healthcare Conference
November 07, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
November 02, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 8, 2023
October 25, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey
October 16, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
October 09, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus Pharmaceuticals Announces Webcast of R&D Day to be Held on October 18, 2023 in New York City
September 27, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus Announces New Qelbree® Data Showing Improvement in ADHD Symptoms
September 09, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Supernus to Participate in the Wells Fargo Healthcare Conference
August 31, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Bethany L. Sensenig Joins Supernus’ Board of Directors
August 21, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
SUPN
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.